MN
$72.58
+0.23
(+0.32%)
As of Oct 22, 2026, 9:30 PM EDT
Price history
Monopar Therapeutics Inc (MNPR) is trading up at $72.58 (+0.32%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Monopar Therapeutics Inc revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — | $0 | $0 |
| Operating income | −$1.19M | −$16.6M | −$3.33M | −$4.32M | −$6.51M | −$9.13M | −$10.5M | −$8.83M | −$16.2M | −$16.7M |
| Net income | −$1.19M | −$16.6M | −$3.23M | −$4.22M | −$6.30M | −$9.10M | −$10.5M | −$8.40M | −$15.6M | −$13.7M |
| EPS (diluted) | — | −$47.25 | −$8.75 | −$11.25 | −$14.50 | −$18.25 | — | — | — | — |
| Balance sheet | ||||||||||
| Cash and equivalents | $2.07M | $8.98M | $6.89M | $13.2M | $16.7M | $20.3M | $8.19M | $7.27M | $45.8M | $61.8M |
| Total assets | $2.90M | $9.93M | $7.32M | $13.4M | $16.9M | $20.5M | $13.2M | $7.35M | $60.3M | $140.7M |
| Total liabilities | $64.5K | $311.9K | $399.6K | $724.2K | $1.18M | $1.58M | $3.14M | $1.76M | $5.25M | $2.89M |
| Shareholders' equity | $2.83M | $9.62M | $6.92M | $12.6M | $15.7M | $18.9M | $10.1M | $5.59M | $55.0M | $137.8M |
| Cash flow | ||||||||||
| Operating cash flow | −$1.19M | −$2.63M | −$2.68M | −$3.02M | −$4.66M | −$7.32M | −$7.23M | −$7.86M | −$6.40M | −$12.2M |
| Share buybacks | — | — | — | — | — | — | — | — | $0 | $35.0M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26†Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | $0 | $0 |
| Operating income | −$1.57M | −$11.1M | −$3.22M | −$3.23M | −$4.09M | −$6.16M | −$5.23M | −$6.64M |
| Net income | −$1.30M | −$10.9M | −$2.62M | −$2.45M | −$3.44M | −$5.20M | −$3.89M | −$5.31M |
| Balance sheet | ||||||||
| Cash and equivalents | $6.02M | $45.8M | $39.7M | $39.5M | $127.7M | $61.8M | $52.5M | $52.8M |
| Total assets | $6.07M | $60.3M | $55.1M | $53.9M | $144.2M | $140.7M | $138.0M | $135.0M |
| Total liabilities | $1.12M | $5.25M | $1.49M | $1.66M | $2.64M | $2.89M | $2.59M | $4.12M |
| Shareholders' equity | $4.95M | $55.0M | $53.6M | $52.2M | $141.6M | $137.8M | $135.4M | $130.9M |
| Cash flow | ||||||||
| Operating cash flow | −$1.07M | −$2.00M | −$5.66M | −$1.08M | −$2.09M | −$3.37M | −$3.47M | −$3.25M |
| Share buybacks | — | $0 | — | — | — | $0 | — | — |
From Monopar Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Monopar Therapeutics Inc
- Headquarters
- Wilmette, Illinois From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International